Skip to main content
profile image
Selected Works of Carlo B. Bifulco, M.D.
Article
Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Blood (2017)
  • Geoffrey L. Uy, Washington University in St. Louis
  • John Godwin, Providence Cancer Center, Portland, OR
  • Michael P Rettig, Washington University in St. Louis
  • Norbert Vey, Clinical Hematology, Paoli-Calmettes Institute, Marseille, France
  • Matthew Foster, University of North Carolina at Chapel Hill
  • Martha L. Arellano, Emory University
  • David A. Rizzieri, Duke University
  • Max S. Topp, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
  • Gerwin Huls, University Medical Center Groningen
  • Bob Lowenberg, Erasmus University Medical Center
  • Giovanni Martinelli, University of Bologna
  • Stefania Paolini, University of Bologna
  • Fabio Ciceri, Vita-Salute San Raffaele University
  • Matteo Giovanni Carrabba, Vita-Salute San Raffaele University
  • Carmen Ballesteros-Merino, Providence Cancer Center, Portland, OR
  • Carlo B Bifulco, Providence Cancer Center, Portland, OR
  • Helene Lelièvre, Centre de Recherche en Cancérologie de Marseille, Servier, Suresnes, France
  • Ross La Motte-Mohs, MacroGenics, Inc., Rockville, MD
  • Daner Li, MacroGenics, Inc., Rockville, MD
  • Jichao Sun, MacroGenics, Inc., Rockville, MD
  • Kenneth Jacobs, MacroGenics, Inc., Rockville, MD
  • Karen Spohn, MacroGenics, Inc., Rockville, MD
  • Nadia Lonsdale, MacroGenics, Inc., Rockville, MD
  • Kathy Tran, MacroGenics, Inc., Rockville, MD
  • Jan Baughman, MacroGenics, Inc., Rockville, MD
  • Michele Shannon, MacroGenics, Inc., Rockville, MD
  • Bernard Fox, Providence Cancer Center, Portland, OR
  • Ezio Bonvini, MacroGenics, Inc., Rockville, MD
  • Jon Wigginton, MacroGenics, Inc., Rockville, MD
  • Jan Davidson-Moncada, MacroGenics, Inc., Rockville, MD
  • John F DiPersio, Washington University in St. Louis
Link
Disciplines
Publication Date
December 7, 2017
DOI
10.1182/BLOOD.V130.SUPPL_1.637.637
Citation Information
Geoffrey L. Uy, John Godwin, Michael P Rettig, Norbert Vey, et al.. "Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome" Blood Vol. 130 (2017) p. 637 - 637
Available at: http://works.bepress.com/carlo-bifulco/71/